The progression of fibrosis can be mitigated through genetic suppression, pharmacological inhibition of CPT1A, and HSC-specific knockdown of CPT1A in mice with choline-deficient models of liver fibrosis 36. This evidence concerns the gene CPT1A and Hepatic fibrosis.